文献速递银屑病与炎症性皮肤病

中重度银屑病患者焦虑与抑郁及古塞奇尤单抗对比阿达木单抗治疗前后变化:3期VOYAGE 2研究结果

Anxiety and depression in patients with moderate-to-severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2018-07-18

VOYAGE 2研究纳入989例中重度银屑病患者,评估古塞奇尤单抗对比安慰剂和阿达木单抗对焦虑抑郁(HADS量表)的改善。第16周,古塞奇尤单抗组基线HADS-A≥8者降至<8的比例显著高于安慰剂组(51.4% vs 25.9%,P<0.001),HADS-D≥8者降至<8的比例也显著高于安慰剂组(59.2% vs 27.0%,P<0.001)。第24周,古塞奇尤单抗组HADS-A<8比例高于阿达木单抗组(58.4% vs 42.9%,P=0.028),HADS-D<8比例对比阿达木单抗组差异未达统计学显著(59.8% vs 46.4%,P=0.079)。

要点

  • 古塞奇尤单抗治疗中重度银屑病,第16周焦虑抑郁改善显著优于安慰剂。
  • 第24周古塞奇尤单抗组焦虑改善比例高于阿达木单抗组,抑郁改善未达显著。
  • PASI改善与焦虑(r=0.27)和抑郁(r=0.25)评分改善相关(P<0.0001)。

核心结论

  • 古塞奇尤单抗治疗与银屑病患者焦虑和抑郁症状评分较安慰剂和阿达木单抗更大幅度的改善相关。

研究设计与样本

  • VOYAGE 2为3期、随机、双盲、安慰剂和阿达木单抗对照研究,共989例患者随机分组并具有基线HADS测量。
  • 患者接受安慰剂(至第16周后交叉至古塞奇尤单抗)、古塞奇尤单抗或阿达木单抗治疗至第24周。

主要发现

  • 基线平均HADS-A评分为6.8±4.2,平均HADS-D评分为5.3±4.2;38.6%患者HADS-A≥8,27.7%患者HADS-D≥8。
  • 第16周,基线HADS-A≥8的古塞奇尤单抗组患者报告HADS-A<8的比例为51.4%,安慰剂组为25.9%(P<0.001)。
  • 第16周,基线HADS-D≥8的古塞奇尤单抗组患者报告HADS-D<8的比例为59.2%,安慰剂组为27.0%(P<0.001)。
  • 第24周,基线HADS-A≥8的古塞奇尤单抗组患者报告HADS-A<8的比例为58.4%,阿达木单抗组为42.9%(P=0.028)。
  • 第24周,基线HADS-D≥8的古塞奇尤单抗组患者报告HADS-D<8的比例为59.8%,阿达木单抗组为46.4%(P=0.079)。

关键数值与推荐

  • HADS包含焦虑(HADS-A)和抑郁(HADS-D)两个亚量表,评分范围0至21分,分数越高症状越重。
  • HADS评分≥8提示工具定义的焦虑或抑郁。
  • 第16周采用更严格阈值HADS≥11时,古塞奇尤单抗组HADS改善也大于安慰剂组。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Anxiety and depression are clinically significant comorbidities associated with psoriasis. Improvements in psoriasis are known to decrease anxiety and depression. Guselkumab, an anti-interleukin-23 monoclonal antibody, has demonstrated efficacy and safety for the treatment of moderate-to-severe psoriasis. OBJECTIVE: Assess improvements in anxiety and depression with guselkumab vs. placebo and adalimumab using the Hospital Anxiety and Depression Scale (HADS). METHODS: In VOYAGE 2, a Phase 3, randomized, double-blind, placebo- and adalimumab-controlled study, patients received placebo (through week 16 followed by crossover to guselkumab), guselkumab, or adalimumab through week 24. HADS consists of two subscales measuring anxiety (HADS-A) and depression (HADS-D), with scores ranging from 0 to 21 and higher scores indicating more severe symptoms. Scores ≥8 indicate instrument-defined anxiety or depression. Severity of psoriasis was assessed using the Psoriasis Area and Severity Index (PASI). RESULTS: Among 989 patients randomized (with baseline HADS measurements), mean HADS-A and HADS-D scores were 6.8 ± 4.2 and 5.3 ± 4.2, respectively; 38.6% of patients reported HADS-A ≥8 and 27.7% HADS-D ≥8 at baseline. At week 16, a significantly greater proportion of guselkumab patients with baseline HADS-A or HADS-D ≥8 reported HADS-A <8 (51.4% vs. 25.9%; P < 0.001) or HADS-D <8 (59.2% vs. 27.0%; P < 0.001) vs. placebo patients. At week 24, a greater proportion of guselkumab patients with baseline HADS-A or HADS-D ≥8 reported HADS-A <8 (58.4% vs. 42.9%; P = 0.028) or HADS-D <8 (59.8% vs. 46.4%; P = 0.079) vs. adalimumab patients. PASI improvements correlated with improvement in anxiety (r = 0.27; P < 0.0001) and depression (r = 0.25; P < 0.0001) scores in patients with baseline HADS-A or HADS-D ≥8. Greater improvements in HADS were also observed at week 16 in guselkumab-treated patients vs. placebo using a more stringent cut-off of HADS ≥11. CONCLUSION: Guselkumab treatment was associated with greater improvements in symptoms of anxiety and depression scores in patients with psoriasis compared with placebo and adalimumab.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Gordon KB, Armstrong AW, Han C, et al. Anxiety and depression in patients with moderate-to-severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study. J Eur Acad Dermatol Venereol. 2018. PMID: 29706008. doi:10.1111/jdv.15012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。